Gilead Sciences’ Latest Tactic? Go Generic

Gilead Sciences NASDAQ GILD has been locked in a heated battle against AbbVie Inc NYSE ABBV for market share in hepatitis C treatment And that battle which has gone on for years has taken a big toll on Gilead Sciences pricing power and profits This week Gilead

Source

The post Gilead Sciences’ Latest Tactic? Go Generic appeared first on Cannabis Stock Picks.

Go to OG News Source
Author: Admin
{authorlink}